Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
4(44%)
Results Posted
100%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
3
33%
Ph phase_3
4
44%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

Recruiting4
unknown2
Completed1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 34 (50.0%)

Trials by Status

unknown222%
completed111%
not_yet_recruiting111%
recruiting444%
terminated111%

Recent Activity

4 active trials
Showing 5 of 9
not_yet_recruitingphase_1

A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer

NCT07560124
recruitingphase_2

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

NCT07227233
recruitingphase_3

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
recruitingphase_3

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

NCT06341621
recruiting

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

NCT06035016
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07560124Phase 1

A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer

Not Yet Recruiting
NCT07227233Phase 2

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Recruiting
NCT06072612Phase 3

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
NCT06341621Phase 3

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

Recruiting
NCT06035016

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Recruiting
NCT03997539Phase 2

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Unknown
NCT01289223Phase 3

A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

Terminated
NCT01419197Phase 3

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Completed
NCT02829008Phase 2

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9